|
General Information
|
|---|
| Symbol | Hsap\ATXN3tr.Q78.Scer\UAS.T:Ivir\HA1 | Species | H. sapiens |
|---|
| Name | | FlyBase ID | FBal0090630 |
|---|
| Feature type | allele | Associated gene | Hsap\ATXN3 |
|---|
|
|---|
| Allele class | |
|---|
| Mutagen | in vitro construct - regulatory fusion, in vitro construct - coding region fusion |
Recent Updates
|
| Description |
What does this section display?
This section contains items that were added to this record for each release.
It currently only tracks new links between this FlyBase report and other
FlyBase data classes (e.g. genes, references, stocks) or controlled
vocabulary terms (e.g. GO, anatomy terms).
What does this section not display?
This section does not currently display links that were removed or gene model changes.
|
| Update Feed |
Click the icon below to subscribe to this FlyBase record and receive updates automatically through your
feed reader.
|
| FB2013_03 |
|
| FB2013_02 |
Controlled Vocabulary Terms
|
| All updates |
Click here to see a list of all updates to this record from FB2010_08 and on.
|
Nature of the Allele
|
|---|
| Allele class | |
|---|
| Mutagen | |
|---|
| Mutations Mapped to the Genome |
|---|
|
|---|
|
| Associated Sequence Data |
|---|
DDBJ
/
EMBL
/
GenBank |
|
|---|
|
|---|
| UniProtKB/Swiss-Prot | |
|---|
| UniProtKB/TrEMBL | |
|---|
|
|---|
| Progenitor genotype | |
|---|
| Nature of the lesion | Construct: A truncated form of Hsap\MJD, consisting of an expanded length glutamine tract (78 repeats) flanked upstream by 12 amino acids and downstream by the carboxy terminal 43 amino acids of Hsap\MJD, is expressed under the control of Scer\UAS regulatory sequences. The Hsap\MJD protein is tagged at the N-terminal end with T:Ivir\HA1. |
|---|
| Carried in construct | ( Martin-Lanneree et al., 2006, Warrick et al., 1999, Mizutani et al., 2005, Jung and Bonini, 2007, Moreno et al., 2002, Gunawardena et al., 2003, Lee et al., 2004, Bilen et al., 2006, Kanuka et al., 2003, Perez et al., 1998, Bonini, 1999, Warrick et al., 1998, Senoo-Matsuda et al., 2005, Kadener et al., 2006, Boeddrich et al., 2006, Umeda-Kameyama et al., 2007, Warrick et al., 2005, Bonini, 2002, Bohm et al., 2010, Ryoo et al., 2007, Mallik and Lakhotia, 2009, Arya et al., 2010, Khurana et al., 2006, Mallik and Lakhotia, 2010, Jung et al., 2009, Vos et al., 2010, Carra et al., 2010, Watson et al., 2008, Park et al., 2011, Ghosh and Feany, 2004, Khurana et al., 2010, Chang et al., 2011, Tonoki et al., 2011, Butler et al., 2012, Liu et al., 2012, Lessing and Bonini, 2008, Bhutani et al., 2012, Chan et al., 2000, Fujikake et al., 2008, Bilen and Bonini, 2007, Li et al., 2008) |
|---|
| Tagged with | ( Warrick et al., 1998, Perez et al., 1998, Bonini, 1999, Warrick et al., 1999, Moreno et al., 2002, Gunawardena et al., 2003, Kanuka et al., 2003, Lee et al., 2004, Mizutani et al., 2005) |
|---|
| Cytology | |
|---|
Phenotypic Data
|
|---|
Phenotypic Class
|
|---|
| ( Warrick et al., 1998, Martin-Lanneree et al., 2006, Warrick et al., 1999, Bonini, 1999, Warrick et al., 2005, Bonini, 2002, Bohm et al., 2010) |
|---|
Phenotype Manifest In
|
|---|
| ( Moreno et al., 2002, Warrick et al., 1998, Mizutani et al., 2005, Martin-Lanneree et al., 2006, Kanuka et al., 2003, Warrick et al., 1999, Bonini, 1999, Senoo-Matsuda et al., 2005, Warrick et al., 2005, Bonini, 2002, Ryoo et al., 2007, Bilen et al., 2006, Mallik and Lakhotia, 2009, Khurana et al., 2006, Mallik and Lakhotia, 2010, Jung et al., 2009, Carra et al., 2010, Park et al., 2011, Bohm et al., 2010, Fujikake et al., 2008) ( Warrick et al., 1998, Warrick et al., 1999, Senoo-Matsuda et al., 2005, Warrick et al., 2005, Bonini, 2002, Bilen et al., 2006, Mallik and Lakhotia, 2009, Ghosh and Feany, 2004, Lessing and Bonini, 2008) |
|---|
Detailed Description
|
|---|
| Expression of Hsap\ATXN3[tr.Q78.Scer\UAS.T:Ivir\HA1] under the control of Scer\GAL4[ninaE.PT] results in inclusion formation, a decrease in polyQ protein solubility and progressive neural loss. At 21 days the number of photoreceptors per ommatidium is reduced in male flies compared to controls. One day old flies expressing a strong insertion of Hsap\ATXN3[tr.Q78.Scer\UAS.T:Ivir\HA1] under the control of Scer\GAL4[GMR.PF] show severe compound eye degeneration. This degeneration is strongly suppressed upon treatment with the HSF1-activating compound 17-AAG at concentrations of 500nM, 1.5µM and 5µM. Treatment at 50nM shows only a moderate therapeutic effect and treatment at 50µM has no effect. The suppression seen with 17-AAG is stronger than is seen with the histone deacetylase inhibitor SB, which shows only a weak effect. Treatment with GA at concentrations of 500nM and 5µM also results in modest suppression of compound eye degeneration, but no suppression is seen at concentrations of 500nM and 50µM. Treatment with RA at concentrations ranging from 50nM to 5µM also effectively suppresses neurodegeneration. No detectable changes are seen when the flies are treated with either CL (1 to 100 µM) or GGA (10µM to 40 mM).
Expression of a strong insertion of Hsap\ATXN3[tr.Q78.Scer\UAS.T:Ivir\HA1] in the nervous system under the control of Scer\GAL4[elav.PLu] significantly decreases the survival rate of flies during their development to adults. This lethality is significantly suppressed upon treatment with the HSF1-activating compound 17-AAG.
Eye discs from flies expressing a weak insertion of Hsap\ATXN3[tr.Q78.Scer\UAS.T:Ivir\HA1] under the control of Scer\GAL4[GMR.PF] contain numerous inclusion bodies in the region posterior to the morphogenetic furrow. Significantly fewer inclusion bodies are seen when the flies are treated with the HSF1-activating compound 17-AAG and the size of the remaining inclusion bodies is significantly reduced. Treatment with 17-AAG also reduces the ratio of the anteroposterior width of the area with cells containing inclusion bodies to that of the area with cells containing diffusely distributed protein. Flies expressing Hsap\MJDtr.Q78.Scer\UAS.T:Ivir\HA1 under the control of Scer\GAL4GMR.PF have a severe eye degeneration phenotype, with loss of external and internal eye structure. The degeneration becomes more severe over the lifetime of the adult fly. Flies expressing Hsap\MJDQ78.Scer\UAS.T:Ivir\HA1 under the control of Scer\GAL4GMR.PF have rough eyes. The severity of the phenotype varies from mild roughness of the eye, through loss of pigment with severely disrupted eye morphology, to reduced eye size. The retina shows cell degeneration. The lamina and medulla show good structure and are normal in size, and the optic chiasm is present, even in flies with a severe phenotype. Large holes are visible in the most lateral part of the lamina, due to separation of the retinal basement membrane from the lamina in flies with moderate or severe phenotypes. The eye morphology progressively degenerates as the flies age. The retina does not deepen as much as normal in pupae expressing Hsap\MJDQ78.Scer\UAS.T:Ivir\HA1 under the control of Scer\GAL4GMR.PF. Pigmentation initiates at the correct time, but only occurs round the periphery of the developing eye. Flies expressing Hsap\MJDQ78.Scer\UAS.T:Ivir\HA1 under the control of Scer\GAL4elav-C155 emerge but show an early death phenotype in weak or moderate expressing P{UAS-Hsap\MJD.tr-Q78} lines. The brains of 4 day old flies appear shrunken compared to 1 day old flies, with the flies dying by 5 days. Gross degeneration of the brain is not seen. The eyes show some irregularity and loss of cell morphology of the rhabdomere lattice in 1 day old flies. A much greater loss of cell integrity is seen in 4 day old flies. Flies expressing Hsap\MJDQ78.Scer\UAS.T:Ivir\HA1 under the control of Scer\GAL4elav-C155 in strong expressing P{UAS-Hsap\MJD.tr-Q78} lines do not survive to adulthood. Flies expressing Hsap\MJDQ78.Scer\UAS.T:Ivir\HA1 under the control of Scer\GAL4how-24B die as embryos or larvae. Expression of Hsap\MJDQ78.Scer\UAS.T:Ivir\HA1 under the control of Scer\GAL4dpp.blk1 has no phenotypic effect. |
|---|
External Data
|
|---|
| Linkouts | |
|---|
Interactions
|
|
|
Phenotypic Class
|
|---|
Enhanced by |
|---|
|
NOT Enhanced by |
|---|
|
Suppressed by |
|---|
|
NOT suppressed by |
|---|
|
Enhancer of |
|---|
|
NOT Enhancer of |
|---|
|
Other |
|---|
|
Phenotype Manifest In
|
|---|
Enhanced by |
|---|
|
NOT Enhanced by |
|---|
|
Suppressed by |
|---|
|
NOT suppressed by |
|---|
|
Enhancer of |
|---|
|
NOT Enhancer of |
|---|
|
Other |
|---|
|
Additional Comments
|
|---|
Genetic Interactions
|
|---|
|
Xenogenetic Interactions
|
|---|
Expression of nej[F2161A.Scer\UAS.T:SV5\V5] in the Scer\GAL4[GMR.PF], Hsap\MJD[tr.Q78.Scer\UAS.T:Ivir\HA1] background results in 15% lethality at the pupal stage. Surviving flies show a reduction in eye size and a greater disruption in ommatidial arrays. Additional co-expression of one copy of P{Sym-UAS-Hsrω} improves the eye morphology and size and reduces pupal death.
Expression of nej[dsRNA.Scer\UAS.cKa] in the Scer\GAL4[GMR.PF], Hsap\MJD[tr.Q78.Scer\UAS.T:Ivir\HA1] background results in >97% lethality at the pharate stage with eye degeneration being dramatically enhanced. Additional co-expression of P{Sym-UAS-Hsrω} robustly suppresses this enhanced eye damage, and also substantially reverses Scer\GAL4[GMR.PF], Hsap\MJD[tr.Q78.Scer\UAS.T:Ivir\HA1] eye degeneration in a dose-dependent manner. Co-expression of P{Sym-UAS-Hsrω} also improves emergence to adult stage in a dose-dependent manner.
The damaged eye phenotype that results from Scer\GAL4[GMR.PF]-mediated expression of Hsap\MJD[tr.Q78.Scer\UAS.T:Ivir\HA1] is suppressed by co-expression of P{Sym-UAS-Hsrω}, and is not further enhanced by co-expression of Pros26[1.B.Scer\UAS] and Prosβ2[1.Scer\UAS]. Co-expression of P{Sym-UAS-Hsrω} still suppresses the damage in Scer\GAL4[GMR.PF], Hsap\MJD[tr.Q78.Scer\UAS.T:Ivir\HA1], Pros26[1.B.Scer\UAS], Prosβ2[1.Scer\UAS] eyes, but the eyes are not rescued to the degree seen in Scer\GAL4[GMR.PF], Hsap\MJD[tr.Q78.Scer\UAS.T:Ivir\HA1] eyes. Hsp68[E407], mrj[E1050] and CG14207[EP1348] are each strong suppressors of the eye degeneration phenotype caused by expression of Hsap\ATXN3[tr.Q78.Scer\UAS.T:Ivir\HA1] under the control of Scer\GAL4[GMR.PU]. External eye pigmentation is restored, and the thickness of the retina is restored towards normal.
DnaJ-1[B345.2], DnaJ-1[EP411], Tpr2[EB7-1A], Ubp64E[E213-1A], wech[JM120], wech[JM265], wech[E546], wech[EP2594], Imp[EP1433] and CG5009[B227.2] are each strong suppressors of the eye degeneration phenotype caused by expression of Hsap\ATXN3[tr.Q78.Scer\UAS.T:Ivir\HA1] under the control of Scer\GAL4[GMR.PU].
CG11700[EP1384], CG8209[B3-Sa], Faf[E659], emb[E2-1A], emb[E128-1A], NFAT[EP1335] and NFAT[EP1508] are each moderate suppressors of the eye degeneration phenotype caused by expression of Hsap\ATXN3[tr.Q78.Scer\UAS.T:Ivir\HA1] under the control of Scer\GAL4[GMR.PU].
Sin3A[B9-E], dbr[EP456], dbr[EP9] and orb2[B8-S] are each weak suppressors of the eye degeneration phenotype caused by expression of Hsap\ATXN3[tr.Q78.Scer\UAS.T:Ivir\HA1] under the control of Scer\GAL4[GMR.PU].
Kdm2[EP3093] is an enhancer of the eye degeneration phenotype caused by expression of Hsap\ATXN3[tr.Q78.Scer\UAS.T:Ivir\HA1] under the control of Scer\GAL4[GMR.PU].
Expression of Hsap\ATXN3[tr.Q78.Scer\UAS.T:Ivir\HA1] under the control of Scer\GAL4[GMR.PU] in the presence of Df(3L)CH20/+ results in lethality and causes severe eye degeneration in pupae.
Df(2L)r10 and Df(2L)PM44 each dominantly enhance the eye degeneration phenotype caused by expression of Hsap\ATXN3[tr.Q78.Scer\UAS.T:Ivir\HA1] under the control of Scer\GAL4[GMR.PU].
Co-expression of mrj[E1050] completely restores normal visual behaviour, and co-expression of CG14207[EP1348] partially restores visual behaviour in 1 day old flies expressing Hsap\ATXN3[tr.Q78.Scer\UAS.T:Ivir\HA1] under the control of Scer\GAL4[GMR.PU] and tested in a phototaxis assay.
Co-expression of Prosβ6[1.B.Scer\UAS] does not enhance the eye degeneration phenotype caused by expression of Hsap\ATXN3[tr.Q78.Scer\UAS.T:Ivir\HA1] under the control of Scer\GAL4[GMR.PU].
In the presence of Prosβ6[1.B.Scer\UAS], CG11700[EP1384] cannot suppress the eye degeneration phenotype caused by expression of Hsap\ATXN3[tr.Q78.Scer\UAS.T:Ivir\HA1] under the control of Scer\GAL4[GMR.PU].
In the presence of Prosβ6[1.B.Scer\UAS], Ubp64E[E213-1A] cannot suppress the eye degeneration phenotype caused by expression of Hsap\ATXN3[tr.Q78.Scer\UAS.T:Ivir\HA1] under the control of Scer\GAL4[GMR.PU].
DnaJ-1[B345.2] and wech[JM265] are each still able to suppress the eye degeneration phenotype caused by expression of Hsap\ATXN3[tr.Q78.Scer\UAS.T:Ivir\HA1] under the control of Scer\GAL4[GMR.PU] when the flies also carry Prosβ6[1.B.Scer\UAS]. Flies expressing both Hsap\MJDQ78.Scer\UAS.T:Ivir\HA1 and debclScer\UAS.T:Ivir\HA1 in their neurons, under the control of Scer\GAL4elav-C155, show a significantly shorter lifespan than flies expressing Hsap\MJDQ78.Scer\UAS.T:Ivir\HA1 alone.
Coexpression of Hsap\MJDQ78.Scer\UAS.T:Ivir\HA1 and debclScer\UAS.T:Ivir\HA1, driven by Scer\GAL4GMR.PF, accelerates the onset of eye neurodegeneration seen in adults expressing Hsap\MJDQ78.Scer\UAS.T:Ivir\HA1. The loss of retinal structure and pigment defects are strongly enhanced by debclScer\UAS.T:Ivir\HA1 expression.
Overexpression of BuffyScer\UAS.cQa enhances the Scer\GAL4GMR.PF; Hsap\MJDQ78.Scer\UAS.T:Ivir\HA1-induced eye neurodegeneration and lethality.
Eyes coexpressing debclScer\UAS.T:Ivir\HA1, BuffyScer\UAS.cQa, and Hsap\MJDQ78.Scer\UAS.T:Ivir\HA1 (all driven by Scer\GAL4GMR.PF) show a significantly weaker degenerative eye phenotype than eyes expressing BuffyScer\UAS.cQa and Hsap\MJDQ78.Scer\UAS.T:Ivir\HA1.
Ectopic expression of debclGS2263, under the control of Scer\GAL4GMR.PF, suppresses the Hsap\MJDQ78.Scer\UAS.T:Ivir\HA1-induced neurodegeneration of the eye. In addition , debclGS2263 markedly rescues the early adult death of flies expressing Hsap\MJDQ78.Scer\UAS.T:Ivir\HA1 in their neurons, driven by Scer\GAL4elav-C155. When Hsap\MJDQ78.Scer\UAS.T:Ivir\HA1 is driven in neurons either by Scer\GAL4Appl.G1a or Scer\GAL4179Y, and combined with Khc9, mutant larval nerves contain axonal blockages. Mutant nerves also contain enlarged axons, some almost four or five times the diameter of those seen in wild-type. Sometimes "holes" lacking organelles are seen within the nerve. |
Complementation & Rescue Data
|
|---|
| Comments | |
|---|
Stocks
( 2 ) |
|---|
| Bloomington | |
|---|
Notes on Origin
|
|---|
|
Discoverer
| |
|---|
| |
|---|
External Crossreferences & Linkouts
|
|---|
| Other Crossreferences |
|---|
| |
|---|
| Linkouts |
|---|
| |
|---|
Synonyms & Secondary IDs
( 4 ) |
|---|
| Reported As |
|---|
| Symbol Synonym | Hsap\ATXN3tr.Q78.Scer\UAS.T:Ivir\HA1
Hsap\MJDQ78.Scer\UAS.T:Ivir\HA1
Hsap\MJDtr.Q78.Scer\UAS.T:Ivir\HA1
|
|---|
| Name Synonym | |
|---|
| Secondary FlyBase IDs |
|---|
| |
|---|
References
( 42 ) |
|---|
|
|---|
| Generate a list of | |
|---|
|
|---|
| List References by type | |
|---|
Recent research papers ( 6 ) |
|---|
| - Bhutani et al., 2012, Cell Death Dis. 3: e428
- Dysregulation of core components of SCF complex in poly-glutamine disorders. [FBrf0219951]
- Butler et al., 2012, PLoS Genet. 8(2): e1002488
- The Mitochondrial Chaperone Protein TRAP1 Mitigates α-Synuclein Toxicity. [FBrf0217423]
- Liu et al., 2012, Nature 482(7386): 519--523
- The microRNA miR-34 modulates ageing and neurodegeneration in Drosophila. [FBrf0217556]
- Chang et al., 2011, PLoS Genet. 7(2): e1001288
- Pathogenic VCP/TER94 Alleles Are Dominant Actives and Contribute to Neurodegeneration by Altering Cellular ATP Level in a Drosophila IBMPFD Model. [FBrf0213008]
- Park et al., 2011, Biochem. Biophys. Res. Commun. 404(2): 638--645
- Normal prion protein in Drosophila enhances the toxicity of pathogenic polyglutamine proteins and alters susceptibility to oxidative and autophagy signaling modulators. [FBrf0212784]
- Tonoki et al., 2011, Genes Cells 16(5): 557--564
- Aging causes distinct characteristics of polyglutamine amyloids in vivo. [FBrf0213535]
|
|---|
Recent reviews (0)
|
|---|
|
All reviews listed in FlyBase were published before 2011 |
|---|
|
|---|